José Javier Serer Ripoll

36 posts

José Javier Serer Ripoll

José Javier Serer Ripoll

@JJSererRipoll

Clinical Oncologist

Katılım Mayıs 2022
206 Takip Edilen112 Takipçiler
Sir Chandler Blog
Sir Chandler Blog@SirChandlerBlog·
La casa natal de Sarmiento 😀
Sir Chandler Blog tweet mediaSir Chandler Blog tweet mediaSir Chandler Blog tweet mediaSir Chandler Blog tweet media
Español
4
9
132
10.6K
José Javier Serer Ripoll retweetledi
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
ME: doing my best to stay updated in oncology!
English
11
73
396
54.2K
José Javier Serer Ripoll retweetledi
Harold J. Burstein, MD, PhD, FASCO
Terrific debate featuring Drs Virginia Borges and Martine Piccart on the role of anthracyclines in early breast cancer. This summary from Dr Piccart captures much of the final recommendation
Harold J. Burstein, MD, PhD, FASCO tweet media
English
3
31
114
10K
José Javier Serer Ripoll retweetledi
Hope Rugo
Hope Rugo@hoperugo·
Big news: approval in the altered population only. Great to have this new option! ⁦@OncoAlert⁩ FDA approves capivasertib with fulvestrant for breast cancer | FDA fda.gov/drugs/resource…
English
2
12
65
6.8K
José Javier Serer Ripoll retweetledi
Ryan Huey, MD, MS
Ryan Huey, MD, MS@ryanhuey·
Oof. 😓 Burnout among oncologists has increased from 34% to 59% over the past 10 years. 22% likely to reduce clinical hours in the next year (up from 16%). #ASCOQLTY23
Ryan Huey, MD, MS tweet media
English
1
21
58
20.2K
José Javier Serer Ripoll retweetledi
Sociedad Argentina de Cardiología
🔵Comunicado Intersocietario: Sociedades de Cardiología reclaman por falta de insumos indispensables
Sociedad Argentina de Cardiología tweet media
Español
30
665
848
177.5K
Gladiador Merval
Gladiador Merval@gladiadormerval·
Alguno sabe quien es Gladiador ? Saludos Gladiador
Español
75
0
86
50.8K
José Javier Serer Ripoll retweetledi
Yakup Ergün
Yakup Ergün@dr_yakupergun·
Assessment of use and impact of chemotherapy in T1aN0 TNBC 1,739 pts (SEER Database) 📌Adjuvant chemotherapy is not associated with benefit on OS (HR, 0.63; 95% CI, 0.35-1.13) or BCSS (HR, 0.95; 95% CI, 0.37-2.43) (CI too wide!) @CBCjournal clinical-breast-cancer.com/article/S1526-…
Yakup Ergün tweet media
English
2
31
77
4.9K
José Javier Serer Ripoll retweetledi
Carlo Palmieri
Carlo Palmieri@cancermedic·
D-TORCH Study: Topical 1% diclofenac ⬇️ incidence of grade 2+ & all grade hand-foot syndrome. #ASCO23 so devilishly simple, easy to implement & a treatment that doesn’t bust the 🐷bank. What’s not to like?
Carlo Palmieri tweet mediaCarlo Palmieri tweet mediaCarlo Palmieri tweet mediaCarlo Palmieri tweet media
English
2
33
108
30.3K
José Javier Serer Ripoll retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
The KM curve everyone’s been waiting for. Adjuvant ribociclib for 3 years significantly improved iDFS in patients with stage II-III HR+ BC, with 25% reduction in the risk of recurrence & a 3-year iDFS delta of 3.3%. #ASCO23
Paolo Tarantino tweet media
English
15
63
229
50.4K
fff
fff@kedesirteee·
que hago? practico o me voy a la pile?
Español
1
0
0
119